Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARPi-FL Imaging in Oral Squamous Cell Carcinomas
NCT03085147Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2017
- Primary completion
- Jul 2027
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib-bodipy FL in oral squamous cell carcinoma (OSCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2017; status: active, not recruiting.
02
Drugs
olaparib-bodipy FL
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT03085147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085147.